Non-invasive detection of esophageal cancer using genetic changes in circulating cell-free DNA

Avicenna Journal of Medical Biotechnology

Volumn 4, Issue 1, 2012, Pages 3-13

  Ghorbian, Saeid ^a   Ardekani, Ali M ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Biomarkers; Early detection; Esophagus neoplasm; Prognosis

Indexed keywords

APC PROTEIN; CELL FREE DNA; CYCLIN D1; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 2P; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 9P; DNA DEGRADATION; DNA METHYLATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; EXON; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; MACROPHAGE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; NON INVASIVE PROCEDURE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84859112678     PISSN: 20082835     EISSN: 20084625     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24(14):2137-2150.
2. Ya W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous cell carcinoma-similarities and differences among anatomical sites. Am J Cancer Res 2011;1(3):275-300.
3. World Cancer Research Fund & American Institute for Cancer Research (1997). Food, nutrition, and the prevention of cancer: A global perspective. American Institute for Cancer Research Washington, DC.
4. Abedi-Ardekani B, Kamangar F, Hewitt SM, Hainaut P, Sotoudeh M, Abnet CC, et al. Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. Gut 2010;59(9):1178-1183.
5. Stewart BW, Kleihues P. Esophageal cancer. World cancer report. Lyon: International Agency for Research on Cancer (IARC); 2003. 5p. Report No.: ISBN 9283204115.
6. Claudia AM, Regiane CJ P, Aureliano CC. Fumonisin as a risk factor to esophageal cancer: a Review. Appli Canc Rese 2009;29(3):102-105.
7. Sorriano JM, Gonzalez L, Catala AI. Mechanism of action os sphin8. golipids and their metabolites in the toxicity of fumonisin B1. Prog Lipid Res 2005;44(6):345-356.
8. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300.
9. Cancer facts and figures 2011. Atlanta, GA: American Cancer Society, 2011.
10. Blot WJ, McLaughlin JK. The changing epidemicology of esophageal cancer. Semin Oncol 1999;26(5 Suppl 15):2-8.
11. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004;99(4):582-588.
12. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int J Epidemiol 2001;30(6):1415-1425.
13. Hongo M. Review article: Barrett's esophagus and carcinoma in Japan. Aliment Pharmacol Ther 2004;20(Suppl 8):50-54.
14. Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol 2008;38(7):464-468.
15. Son JI, Park HJ, Song KS, Kim KJ, Lee CY, Lee SI, et al. A single center's 30 years' experience of esophageal adenocarcinoma. Korean J Intern Med 2001;16(4):250-253.
16. Sadjadi A, Marjani H, Semnani S, Nasseri Moghaddam S. Esophageal cancer in Iran: A review. Mid East J Can 2010;1(1):5-14.
17. Ojala K, Sorri M, Jokinen K, Kairaluoma M. Symptoms of carcinoma of the oesophagus. Med J Aust 1982;1(9):384-385.
18. Danoff B, Cooper J, Klein M. Primary adenocarcinoma of the upper esophagus. Clin Radiol 1978;29(5):519-522.
19. Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001;19(7):1970-1975.
20. Jacobson BC, Hirota W, Baron TH, Leighton JA, Faigel DO. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2003;57(7):817-822.
21. Nishimura Y, Osugi H, Inoue K, Takada N, Takamura M, Kinosita H. Bronchoscopic ultrasonography in the diagnosis of tracheobronchial invasion of esophageal cancer. J Ultrasound Med 2002;21(1):49-58.
22. Levy RM, Wizorek J, Shende M, Luketich JD. Laparoscopic and thoracoscopic esophagectomy. Adv Surg 2010;44:101-116.
23. De Graaf GW, Ayantunde AA, Parsons SL, Duffy JP, Welch NT. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Onco 2007;33(8):988-992.
24. Choi J, Kim SG, Kim JS, Jung HC, Song IS. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010;24(6):1380-1386.
25. Mariette C, Seitz JF, Maillard E, Mornex F, Thomas PA, Raoul J, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901. J Clin Oncol 2010;28(Suppl 15):4005.
26. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006;19(6):425-432.
27. Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH. Molecular biology of esophageal cancer. Onkologie 2004;27(2):200-206.
28. Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003;91(3):476-485.
29. Dong M, Ma G, Tu W, Guo KJ, Tian YL, Dong YT. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol 2005;11(14):2162-2165.
30. Putz A, Hartmann AA, Fontes PR, Alexandre CO, Silveira DA, Klug SJ, et al. TP53 mutation pattern of esophageal squamous cell carcinomas in a high risk area (Southern Brazil): role of life style factors. Int J Cancer 2002;98(1):99-105.
31. Robert V, Michel P, Flaman JM, Chiron A, Martin C, Charbonnier F, et al. High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis 2000;21(4):563-565.
32. Wang LD, Zhou Q, Hong JY, Qiu SL, Yang CS. p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. Cancer 1996;77(7):1244-1249.
33. Shi ST, Yang GY, Wang LD, Xue Z, Feng B, Ding W, et al. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999;20(4):591-597.
34. Abbaszadegan MR, Raziee HR, Ghafarzadegan K, Shakeri MT, Afsharnezhad S, Ghavamnasiry MR. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer 2005;36(1):47-54.
35. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007;56(1):13-19.
36. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang HY, Rhyu MG, et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 1994;54(23):6094-6096.
37. Taghavi N, Biramijamal F, Sotoudeh M, Khademi H, Malekzadeh R, Moaven O, et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer 2010;10:138.
38. Abbaszadegan MR, Raziee HR, Ghafarzadegan K, Ghavamnasiry MR. p16/INK4a promoter hypermethylation in serum, blood and tumor of patients with esophageal squamous cell carcinoma. IJBMS 2004;6(4):4-9.
39. Hardie LJ, Darnton SJ, Wallis YL, Chauhan A, Hainaut P, Wild CP, et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005;217(2):221-230.
40. Xing EP, Nie Y, Wang LD, Yang GY, Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 1999;20(1):77-84.
41. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 2004;111(2):224-228.
42. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5(10):2704-2713.
43. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001;10(7):721-733.
44. Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA 1992;15;89(8):3385-3388.
45. Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol 1999;30(12):1508-1514.
46. Powell SM, Papadopoulos N, Kinzler KW, Smolinski KN, Meltzer SJ. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 1994;107(6):1759-1763.
47. Wu DL, Sui FY, Jiang XM, Jiang XH. Methylation in esophageal carcinogenesis. World J Gastroenterol 2006;12(43):6933-6940.
48. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 1996;69(3):225-235.
49. Kawakubo H, Ozawa S, Ando N, Kitagawa Y, Mukai M, Ueda M, et al. Alterations of p53, cyclin D1 and pRB expression in the carcinogenesis of esophageal squamous cell carcinoma. Oncol Rep 2005;14(6):1453-1459.
50. Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, et al. Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol 2007;34(2 Suppl 1):S2-6.
51. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: over expression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 1999;23(10):1010-1018.
52. Andolfo I, Petrosino G, Vecchione L, De Antonellis P, Capasso M, Montanaro D, et al. Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer 2011;11:126.
53. Ikeguchi M, Unate H, Maeta M, Kaibara N. Detection of loss of heterozygosityat microsatellite loci in esophageal squamous cell carcinoma. Oncology 1999;56(2):164-168.
54. Muzeau F, Flejou JF, Belghiti J, Thomas G, Hamelin R. Infrequent microsatellite instability in oesophageal cancers. Br J Cancer 1997;75(9):1336-1339.
55. Fitzgerald RC, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis 1998;16(2):63-80.
56. Scaros O, Fisler R. Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic. Biotechniques 2005;Suppl:30-32.
57. Cho WC. Proteomics-leading biological science in the 21st century. Sci J 2004;56:14-17.
58. Ardekani AM, Petricoin EF 3rd, Hackett JL. Molecular diagnostics: an FDA perspective. Expert Rev Mol Diagn 2003;3(2):129-140.
59. Ardekani AM, Liotta LA, Petricoin EF 3rd. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002;2(4):312-320.
60. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572-577.
61. Ardekani AM, Akhondi MM, Sadeghi MR. Application of genomic and proteomic technologies to early detection of cancer. Arch Iran Med 2008;11(4):427-434.
62. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94(20):1576-1578.
63. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85(4):350-355.
64. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112(1):40-46.
65. Leman ES, Getzenberg RH. Biomarkers for prostate cancer. J Cell Biochem 2009;108(1):3-9.
66. Quillien V, Raoul JL, Laurent JF, Meunier B, Le Prise E. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Oncol Rep 1998;5(6):1561-1565.
67. Chatterjee M, Wojciechowski J, Tainsky MA. Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput. Methods Mol Biol 2009;520:21-38.
68. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581(5):795-799.
69. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008;452(7187):553-563.
70. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300(5618):455.
71. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452(7187):571-579.
72. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene expression patterns. Nature 2008;452(7187):564-570.
73. Zhu J, Yao X. Use of DNA methylation for cancer detection: promises and challenges. Int J Biochem Cell Biol 2009;41(1):147-154.
74. Mandel P, Bieth R. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948;142(3-4):241-243.
75. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987;23(6):707-712.
76. Van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010;43(1-2):26-36.
77. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61(4):1659-1665.
78. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998;17(1):89-97.
79. Suzuki N, Kamataki A, Yamaki J, Homma Y. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 2008;387(1-2):55-58.
80. Choi JJ, Reich CF, 3rd, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 2005;115(1):55-62.
81. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14(9):985-990.
82. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37(3):646-650.
83. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002;321(1-2):77-87.
84. Fatouros IG, Destouni A, Margonis K, Jamurtas AZ, Vrettou C, Kouretas D, et al. Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. Clin Chem 2006;52(9):1820-1824.
85. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46(3):319-323.
86. Fournié GJ, Martres F, Pourrat JP, Alary C, Rumeau M. Plasma DNA as cell death marker in elderly patients. Gerontology 1993;(39):215-221.
87. Atamaniuk J, Vidotto C, Tschan H, Bachl N, Stuhlmeier KM, Muller MM. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem 2004;50(9):1668-1670.
88. Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004;205(2):173-180.
89. Laktionov PP, Tamkovich SN, Rykova EY, Bryzgunova OE, Starikov AV, Kuznetsova NP, et al. Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids 2004;23(6-7):879-883.
90. Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, et al. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002;9(1):71-76.
91. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21(21):3902-3908.
92. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol 2006;12(24):3911-3914.
93. Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 2005;11(4):1394-1399.
94. Banki F, Mason RJ, Oh D, Hagen JA, DeMeester SR, Lipham JC, et al. Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch Surg 2007;142(6):533-539.
95. Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, et al. Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 2007;27(4C):2737-2741.
96. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59(1):67-70.
97. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92(22):1805-1811.
98. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7(10):3135-3138.
99. Liu JB, Qiang FL, Dong J, Cai J, Zhou SH, Shi MX, et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol 2011;17(44):4917-4921.
100. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002;48(8):1186-1193.
101. Eisenberger F, Knoefel T, Peiper M, Merkert P, Yekebas EF, Scheunemann P, et al. Squamous cell carcinoma of the esophagus can be detected by microsatellite analysis in tumor and serum. Clin Can Res 2003;(15):4178-4183.